Lenalidomide in combination with bortezomib and dexamethasone is now listed on the PBS for the treatment of all patients newly diagnosed with multiple myeloma (NDMM), irrespective of transplant eligibility. Access to the combination as a first line treatment has been welcomed by clinicians and consumers. Haematologist Professor Miles Prince said in a statement that maximising ...
Triplet therapy on PBS for all patients with newly-diagnosed MM
4 Jun 2020